Manufactures active pharmaceutical ingredients (APIs) and industrial chemicals across two segments. The Pharmaceutical segment, which contributed 54.2% of FY26 segment revenue at ₹1,396.25 crore, makes Ibuprofen — where it is the largest global producer with 12,000 MTPA capacity — alongside a diversifying portfolio of non-Ibuprofen APIs such as Paracetamol, Metformin, Clopidogrel, Pantoprazole and Minoxidil, with the non-Ibuprofen share of pharma revenue rising from 18% in FY21 to 37% in FY26. The Chemical segment, 45.0% of segment revenue at ₹1,160.53 crore, produces Ethyl Acetate (1,20,000 MTPA), Acetic Anhydride (32,000 MTPA) and the newly commissioned Triacetin for backward integration, and was running at 98-100% capacity utilisation in Q4 FY26. Operations span 11 dedicated manufacturing units, with 14 USFDA DMFs and 21 EDQM CEPs in regulatory coverage, and products reach 80 countries. Q4 FY26 was the highest-ever quarter at ₹619 crore, lifting full-year revenue to ₹2,319.06 crore with EBITDA margin at 12.04%. Materials form the largest cost line at 64.8% of revenue, with employee cost at 10.7% and other opex at 13.6%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical (54%), Chemical (45%). Asset-heavy API manufacturer and specialty chemicals producer with backward integration
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 |
| EBITDA (ex other income) | 244 | 226 | 231 | 202 | 258 |
| margin % | 11.2 | 10.2 | 10.8 | 9.7 | 11.1 |
| Owners' profit | 168 | 139 | 134 | 101 | 138 |
| EPS, as reported (₹) | 28.56 | 23.70 | 22.90 | 3.44 | 4.69 |
| ROE % · ROCE % | 12.0 · 16.1 | 9.2 · 13.1 | 8.3 · 11.7 | 6.0 · 8.6 | 7.7 · 10.5 |
| Debt / equity (x) | 0.03 | 0.05 | 0.02 | 0.07 | 0.07 |
| Cash from operations | 93 | 122 | 290 | 179 | 214 |
| Capex | (153) | (212) | (274) | (214) | (173) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 |
| Profit before tax | 26 | 28 | 45 | 46 | 40 | 28 | 71 | 87 |
| Net profit | 19 | 21 | 31 | 34 | 30 | 21 | 53 | 64 |
| EPS (₹) | 3.26 | 3.50 | 1.07 | 1.16 | 1.02 | 0.70 | 1.81 | 2.20 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Chemical | 875 | 34.0 |
| Pharmaceutical | 1,060 | 41.1 |
| Unallocated | 15 | 0.6 |
| - Chemical | 285 | 11.1 |
| - Pharmaceutical | 336 | 13.0 |
| - Unallocated | 7 | 0.3 |
| Total, before eliminations | 2,578 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Audio Recording of Business Update Call Shared with Investors and Analysts | investor communications | low | — | — |
| 10 Sept 2026 · IOL Chemicals to hold business update call with investors on Sep 11 | board shareholder meetings | low | — | — |
| 9 Sept 2026 · IOLCP to invest Rs 495 crore in three manufacturing expansions | capex operations | high | — | — |
| 2 Sept 2026 · 39th AGM: All 3 Resolutions Passed Including Director Reappointment | board shareholder meetings | medium | — | — |
| 2 Sept 2026 · IOL Chem and Pharma 39th AGM: All 3 resolutions passed | board shareholder meetings | medium | — | — |
| 26 Aug 2026 · IOL Chem and Pharma to meet analysts on 3 Sept 2026 | board shareholder meetings | low | — | — |
| 20 Aug 2026 · IOL CP Q1 FY27: Revenue up 37%, PAT up 90%, guides 15-20% growth | investor communications | medium | — | — |
| 18 Aug 2026 · Newspaper notice on physical shares demat window | compliance | minimal | — | — |
| 13 Aug 2026 · IOL Chemicals shares Q1 FY2027 earnings call recording link | investor communications | low | — | — |
| 12 Aug 2026 · Q1 FY27 Investor Presentation: Strong Growth with FY27 Guidance | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| SUN PHARMACEUTICAL IND L |
| 4,41,471 |
| 36.5 |
| 5.26 |
| 23.7 |
| 13.7 |
| 17.5 |
| 11.8 |
| 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 34.0 | 28.9 | 94 of 169 | 45% |
| P/B | 3.2 | 3.3 | 79 of 163 | 52% |
| ROCE | 9.7 | 10.8 | 102 of 183 | 45% |
| ROE | 7.7 | 10.4 | 106 of 171 | 38% |
| Debt / Equity | 0.1 | 0.1 | 77 of 171 | 55% |
| EBITDA margin | 14.8 | 17.5 | 93 of 165 | 44% |
| Revenue growth | 37.1 | 16.3 | 33 of 161 | 80% |
| Profit growth | 89.8 | 30.9 | 39 of 158 | 76% |
| Market cap | 5724 | 839 | 57 of 182 | 69% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
